

Special Issue

HPV Vaccination Policies/Strategies

Message from the Guest Editors

On 17 November 2020, the World Health Organization (WHO) launched the Global Strategy to Accelerate the Elimination of Cervical Cancer. This is the first time that 194 countries have made a joint commitment to eliminate a cancer. The HPV vaccine is considered to be the most cost-effective and effective way to prevent cervical cancer. However, the HPV vaccine does not have full coverage at present, so we should strengthen the popularization of HPV vaccine education, vaccination, and early prevention, so that more and more women of the right age can have the danger of cervical cancer removed as soon as possible. We welcome you to submit articles, reviews, case studies, or other types of papers discussing HPV vaccination implementation, monitoring, research, programs, improving equity in HPV vaccination, policies related to HPV vaccination, and social as well as behavioral science strategies with which to support vaccine acceptance. We look forward to receiving your contributions.

Guest Editors

Dr. Spring Chenoa Cooper

Community Health and Social Sciences, CUNY Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA

Dr. Peter Agyei-Baffour

Department of Health Policy, University of Michigan, Ann Arbor, MI, USA

Dr. Raghunadharao Digumarti

KIMS ICON Hospital, Visakhapatnam, India

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/147799

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).